论文部分内容阅读
目的探讨依达拉奉联合醒脑静治疗急性脑出血的临床疗效。方法选取急性脑出血患者73例,随机将其分为两组,观察组40例患者给予依达拉奉联合醒脑静治疗,对照组33例患者给予醒脑静治疗,比较两组患者的临床疗效。结果观察组患者治疗总有效率为95.0%,明显高于对照组的72.7%,差异有统计学意义(P<0.05);两组患者神经功能缺损评分均较治疗前降低,且观察组降低更明显,差异均有统计学意义(均P<0.05);两组患者治疗过程中均无严重不良反应发生。结论依达拉奉联合醒脑静注射液治疗急性脑出血疗效优于单用醒脑静注射液治疗,两药联合能有效改善患者的神经功能缺损,并提高总体疗效。
Objective To investigate the clinical efficacy of edaravone combined with xingnaojing in treating acute cerebral hemorrhage. Methods A total of 73 patients with acute cerebral hemorrhage were randomly divided into two groups. 40 patients in the observation group were treated with edaravone combined with xingnaojing, while 33 in the control group were treated with xingnaojing. The clinical outcomes of two groups were compared Efficacy. Results The total effective rate of observation group was 95.0%, which was significantly higher than that of control group (72.7%), the difference was statistically significant (P <0.05); the score of neurological deficit in both groups was lower than before treatment, and the observation group decreased more Obviously, the differences were statistically significant (both P <0.05); no serious adverse reactions occurred in both groups during the course of treatment. Conclusion The combination of edaravone and xingnaojing injection in the treatment of acute intracerebral hemorrhage is better than that of xingnaojing injection alone. The combination of two drugs can effectively improve the patients’ neurological deficits and improve the overall curative effect.